Post by Alira Health

June is Myasthenia Gravis Awareness Month. We mark this occasion at Alira Health with the launch of a four-part educational series on what makes product development in myasthenia gravis distinct. This week, we explore the role of patient-reported outcomes in myasthenia gravis clinical trials, including how MG-ADL helps connect treatment benefit to patients’ daily functioning. Follow the series to learn more about myasthenia gravis product development and join us in raising awareness around this rare neuromuscular autoimmune condition. Stay tuned for next week’s edition! #MGAwarenessMonth